<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02224118</url>
  </required_header>
  <id_info>
    <org_study_id>CR016429</org_study_id>
    <secondary_id>JNS030-JPN-01</secondary_id>
    <nct_id>NCT02224118</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics, and Pharmacodynamics Study of Single Dose of CNTO 3649 in Healthy Adult Men and Multiple Doses of CNTO 3649 in Participants With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Safety, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Dose of CNTO 3649 in Healthy Adult Men and Multiple Subcutaneous Doses of CNTO 3649 in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Pharmaceutical K.K.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Pharmaceutical K.K.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety (adverse events, weight, blood&#xD;
      pressure, pulse rate, body temperature, abdominal ultrasonography, standard 12-lead&#xD;
      electrocardiography, and laboratory tests) of CNTO 3649 when administered once by&#xD;
      subcutaneous injection in healthy adult Japanese men or once a week for 4 weeks in Japanese&#xD;
      participants with type 2 diabetes mellitus (disorder in which there is decreased insulin in&#xD;
      the body or the body's insulin is not effective, resulting in high blood sugar, increased&#xD;
      thirst and urine, and many other side effects).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, multi-arm and open-label (all knew the intervention of study) study to&#xD;
      explore the safety, pharmacodynamics (the study of how drugs act on the body) and&#xD;
      pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over&#xD;
      time) of CNTO 3649. The study has been divided in Part 1 and 2. Part 1 includes healthy adult&#xD;
      Japanese men and Part 2 includes Japanese participants with type 2 diabetes mellitus. The&#xD;
      healthy adult Japanese men in part 1 will receive a single dose of either 10, 30, 100 or 300&#xD;
      microgram/milliliter (mcg/mL) of CNTO 3649 and participants in part 2 will receive&#xD;
      subcutaneous doses of either 30 or 100 mcg/mL of CNTO 3649 once a week for 4 weeks. The study&#xD;
      will have a Screening period of 28 days for Part 1 and 42 days for Part 2. Participants will&#xD;
      primarily be assessed for safety (adverse events, weight, blood pressure, pulse rate, body&#xD;
      temperature, abdominal ultrasonography, standard 12-lead electrocardiography, and laboratory&#xD;
      test). The total duration of study will be 57 days for Part 1 and 92 days for Part 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</measure>
    <time_frame>Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between administration of study drug and up to 57 for CNTO 3649 10, 30, 100 and 300 microgram per kilogram (mcg/kg) (Part 1); Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2) that would be absent before treatment or that may worsen relative to pre-treatment state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax)</measure>
    <time_frame>Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)</time_frame>
    <description>Maximum Observed Serum Concentration (Cmax) will be observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Serum Concentration (Tmax)</measure>
    <time_frame>Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)</time_frame>
    <description>Time to Reach Maximum Observed Serum Concentration (Tmax) will be observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Elimination Half Life (t1/2)</measure>
    <time_frame>Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)</time_frame>
    <description>Terminal phase elimination half-life is the time measured for the serum concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration Time Curve From Time Zero to Last Measurable Concentration (AUC[0 - last])</measure>
    <time_frame>Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)</time_frame>
    <description>Area Under the Serum Concentration Time Curve From Time Zero to Last Measurable Concentration (AUC[0 - last]) will be observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Zero to Infinity (AUC [0 - infinity])</measure>
    <time_frame>Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)</time_frame>
    <description>Area Under the Concentration-time Curve From Zero to Infinity (AUC [0 - infinity]) will be observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Systemic Clearance (CL/F)</measure>
    <time_frame>Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after subcutaneous dose (apparent systemic clearance) is influenced by the fraction of the dose absorbed (bioavailability).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after subcutaneous dose (Vz/F) is influenced by the fraction absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage Change From Baseline in Blood Glucose Values, Serum Insulin Concentration, and Serum C-Peptide Concentration</measure>
    <time_frame>Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)</time_frame>
    <description>Mean percentage change from baseline in blood glucose values, serum insulin concentration, and serum c-peptide concentration will be observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weighted Average Blood Glucose (WAG) Level</measure>
    <time_frame>Day -1 (Predose) and 24</time_frame>
    <description>The WAG level is calculated as: WAG = Area under concentration (AUC) 24 /24 hours) the day before the first injection and on treatment Day 24 for CNTO 3649 30 or 100 mcg/kg for part 2 participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Haemoglobin (Hb) A1c at Day 36 and 50</measure>
    <time_frame>Baseline, Day 36 and 50</time_frame>
    <description>Change From Baseline in Glycosylated Haemoglobin (Hb) A1c at Day 36 and 50 will be observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Exhibiting Anti-Drug Antibodies for CNTO 3649 at any Visit</measure>
    <time_frame>Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)</time_frame>
    <description>Number of participants exhibiting anti-drug antibodies for CNTO 3649 will be observed.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>CNTO 3649 10 mcg/kg (single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 10 microgram per kilogram (mcg/kg) of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CNT0 3649 30 mcg/kg (single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CNTO 3649 100 mcg/kg (single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CNTO 3649 300 mcg/kg (single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 300 microgram per kilogram (mcg/kg) of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CNT0 3649 30 mcg/kg (multiple dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with type 2 diabetes mellitus will be administered 30 mcg/kg CNTO 3649 as subcutaneous injection once a week for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CNTO 3649 100 mcg/kg (multiple dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with type 2 diabetes mellitus will be administered 100 mcg/kg CNTO 3649 as subcutaneous injection once a week for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNTO 3649 10 mcg/kg</intervention_name>
    <description>A single dose of 10 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.</description>
    <arm_group_label>CNTO 3649 10 mcg/kg (single dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNT0 3649 30 mcg/kg</intervention_name>
    <description>A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 30 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.</description>
    <arm_group_label>CNT0 3649 30 mcg/kg (multiple dose)</arm_group_label>
    <arm_group_label>CNT0 3649 30 mcg/kg (single dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNTO 3649 100 mcg/kg</intervention_name>
    <description>A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 100 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.</description>
    <arm_group_label>CNTO 3649 100 mcg/kg (multiple dose)</arm_group_label>
    <arm_group_label>CNTO 3649 100 mcg/kg (single dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNTO 3649 300 mcg/kg</intervention_name>
    <description>A single dose of 300 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.</description>
    <arm_group_label>CNTO 3649 300 mcg/kg (single dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Part 1&#xD;
&#xD;
          -  Weighs greater than or equal to (&gt;=) 50 kilogram (kg) and less than (&lt;) 100 kg and has&#xD;
             a body mass index (BMI) of &gt;= 18.5 and &lt;25.0 at the time of screening tests&#xD;
&#xD;
          -  Is a non-smoker, or is able to refrain from smoking from 2 days before screening tests&#xD;
             until completion of post-treatment examinations or follow-up investigations&#xD;
&#xD;
          -  Is able to refrain from consuming alcohol from 2 days before screening tests until&#xD;
             completion of screening tests, from 2 days before hospitalization (Day -4) until after&#xD;
             discharge (Day 8), from 2 days before clinic visits (Days 13 and 20) until completion&#xD;
             of tests at clinic visits (Days 15 and 22), and from 2 days before post-treatment&#xD;
             examinations or follow-up investigations until completion of post-treatment&#xD;
             examinations or follow-up investigations&#xD;
&#xD;
          -  Has agreed to use a medically acceptable form of contraception (example [eg], condoms)&#xD;
             from the day of hospitalization (Day -2) until completion of post-treatment&#xD;
             examinations or follow-up investigations&#xD;
&#xD;
          -  Has no clinically problematic abnormalities in medical examinations and tests before&#xD;
             study treatment&#xD;
&#xD;
        Part 2&#xD;
&#xD;
          -  Weighs &gt;= 50 kg and &lt;100 kg and has a BMI of &gt;=18.5 and &lt;37.0 at the time of screening&#xD;
             tests&#xD;
&#xD;
          -  Was diagnosed with type 2 diabetes mellitus at least 3 months before screening tests&#xD;
             and this is being stably managed with dietary modification, exercise therapy, or&#xD;
             sulfonylureas or biguanides If sulfonylureas or biguanides are being used, these have&#xD;
             been used at a fixed dosage to stably manage the disease since at least 3 months&#xD;
             before screening tests&#xD;
&#xD;
          -  If the participant has hyperlipidemia, this has been stably managed with&#xD;
             antihyperlipidemic drugs at a fixed dosage since at least 3 months before screening&#xD;
             tests&#xD;
&#xD;
          -  If the participant has hypertension, this has been stably managed with&#xD;
             antihypertensive drugs at a fixed dosage since at least 3 months before screening&#xD;
             tests&#xD;
&#xD;
          -  Is a non-smoker, or is able to refrain from smoking during the hospitalization period&#xD;
             and from 1 day before clinic visit days until completion of tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Part 1&#xD;
&#xD;
          -  Has or has had hepatic, renal, central nervous system (including psychiatric),&#xD;
             cardiovascular, respiratory, gastrointestinal, hematopoietic, ophthalmic, infectious,&#xD;
             or endocrine disease that would make the participant unsuitable as a study participant&#xD;
&#xD;
          -  Has had a malignant tumor within 5 years before study treatment&#xD;
&#xD;
          -  Has undergone surgery that would make the participant unsuitable as a study&#xD;
             participant within 12 weeks before screening tests&#xD;
&#xD;
          -  Has or had acute disease that occurred within 7 days before study treatment&#xD;
&#xD;
          -  Has or has had an eating disorder (pathological anorexia or bulimia)&#xD;
&#xD;
        Part 2&#xD;
&#xD;
          -  If only dietary modification and exercise therapy are being used, fasting blood&#xD;
             glucose is &lt;130 milligram per deciliters (mg/dL) or &gt;= 270 mg/dL in screening tests&#xD;
             and at hospitalization (Day -1). If oral antihyperglycemic drugs are being used,&#xD;
             fasting blood glucose is &lt;100 mg/dL or &gt;= 240 mg/dL at the time of screening tests and&#xD;
             &lt;120 mg/dL or &gt;= 270 mg/dL at hospitalization (Day -1)&#xD;
&#xD;
          -  If only dietary modification and exercise therapy are being used, HbA 1C at the time&#xD;
             of Screening tests is &lt;6% or &gt;= 10 percent (%). If oral antihyperglycemic drugs are&#xD;
             being used, HbA 1C at the time of screening tests is &lt;6% or &gt;=9%&#xD;
&#xD;
          -  Has blood pressure or a pulse rate that is outside of the following ranges, or has&#xD;
             hypertension and blood pressure or a pulse rate that is outside of the following&#xD;
             ranges despite taking an antihypertensive drug at the same dosage since at least 3&#xD;
             months before screening tests&#xD;
&#xD;
          -  Has or has had type 1 diabetes mellitus&#xD;
&#xD;
          -  Has or has had autoimmune diabetes mellitus&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Pharmaceutical K.K., Japan Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Pharmaceutical K.K.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fukukoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=2352&amp;filename=CR016429_CSR.pdf</url>
    <description>Safety, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Dose of CNTO 3649 in Healthy Adult Men and Multiple Subcutaneous Doses of CNTO 3649 in Patients With Type 2 Diabetes Mellitus</description>
  </link>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>August 21, 2014</study_first_submitted>
  <study_first_submitted_qc>August 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2014</study_first_posted>
  <last_update_submitted>September 8, 2014</last_update_submitted>
  <last_update_submitted_qc>September 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>CNTO 3649</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02224118
org study id: CR016429
secondary id: JNS030-JPN-01
nct id: NCT02224118
lead sponsor: 
has dmc: No
The purpose of this study is to investigate the safety (adverse events, weight, blood
      pressure, pulse rate, body temperature, abdominal ultrasonography, standard 12-lead
      electrocardiography, and laboratory tests) of CNTO 3649 when administered once by
      subcutaneous injection in healthy adult Japanese men or once a week for 4 weeks in Japanese
      participants with type 2 diabetes mellitus (disorder in which there is decreased insulin in
      the body or the body's insulin is not effective, resulting in high blood sugar, increased
      thirst and urine, and many other side effects).
This is a Phase 1, multi-arm and open-label (all knew the intervention of study) study to
      explore the safety, pharmacodynamics (the study of how drugs act on the body) and
      pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over
      time) of CNTO 3649. The study has been divided in Part 1 and 2. Part 1 includes healthy adult
      Japanese men and Part 2 includes Japanese participants with type 2 diabetes mellitus. The
      healthy adult Japanese men in part 1 will receive a single dose of either 10, 30, 100 or 300
      microgram/milliliter (mcg/mL) of CNTO 3649 and participants in part 2 will receive
      subcutaneous doses of either 30 or 100 mcg/mL of CNTO 3649 once a week for 4 weeks. The study
      will have a Screening period of 28 days for Part 1 and 42 days for Part 2. Participants will
      primarily be assessed for safety (adverse events, weight, blood pressure, pulse rate, body
      temperature, abdominal ultrasonography, standard 12-lead electrocardiography, and laboratory
      test). The total duration of study will be 57 days for Part 1 and 92 days for Part 2.
allocation: Non-Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
time frame: Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)
description: An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between administration of study drug and up to 57 for CNTO 3649 10, 30, 100 and 300 microgram per kilogram (mcg/kg) (Part 1); Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2) that would be absent before treatment or that may worsen relative to pre-treatment state.
measure: Maximum Observed Serum Concentration (Cmax)
time frame: Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)
description: Maximum Observed Serum Concentration (Cmax) will be observed.
measure: Time to Reach Maximum Observed Serum Concentration (Tmax)
time frame: Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)
description: Time to Reach Maximum Observed Serum Concentration (Tmax) will be observed.
measure: Terminal Phase Elimination Half Life (t1/2)
time frame: Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)
description: Terminal phase elimination half-life is the time measured for the serum concentration to decrease by one half.
measure: Area Under the Serum Concentration Time Curve From Time Zero to Last Measurable Concentration (AUC[0 - last])
time frame: Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)
description: Area Under the Serum Concentration Time Curve From Time Zero to Last Measurable Concentration (AUC[0 - last]) will be observed.
measure: Area Under the Concentration-time Curve From Zero to Infinity (AUC [0 - infinity])
time frame: Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)
description: Area Under the Concentration-time Curve From Zero to Infinity (AUC [0 - infinity]) will be observed.
measure: Apparent Systemic Clearance (CL/F)
time frame: Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)
description: Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after subcutaneous dose (apparent systemic clearance) is influenced by the fraction of the dose absorbed (bioavailability).
measure: Apparent Volume of Distribution (Vz/F)
time frame: Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)
description: Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after subcutaneous dose (Vz/F) is influenced by the fraction absorbed.
measure: Mean Percentage Change From Baseline in Blood Glucose Values, Serum Insulin Concentration, and Serum C-Peptide Concentration
time frame: Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)
description: Mean percentage change from baseline in blood glucose values, serum insulin concentration, and serum c-peptide concentration will be observed.
measure: Weighted Average Blood Glucose (WAG) Level
time frame: Day -1 (Predose) and 24
description: The WAG level is calculated as: WAG = Area under concentration (AUC) 24 /24 hours) the day before the first injection and on treatment Day 24 for CNTO 3649 30 or 100 mcg/kg for part 2 participants.
measure: Change From Baseline in Glycosylated Haemoglobin (Hb) A1c at Day 36 and 50
time frame: Baseline, Day 36 and 50
description: Change From Baseline in Glycosylated Haemoglobin (Hb) A1c at Day 36 and 50 will be observed.
measure: Number of Participants Exhibiting Anti-Drug Antibodies for CNTO 3649 at any Visit
time frame: Day 1 to 57 for CNTO 3649 10, 30, 100 and 300 mcg/kg (Part 1) or Day 1 to 92 for CNTO 3649 30 and 100 mcg/kg (Part 2)
description: Number of participants exhibiting anti-drug antibodies for CNTO 3649 will be observed.
arm group label: CNTO 3649 10 mcg/kg (single dose)
arm group type: Experimental
description: A single dose of 10 microgram per kilogram (mcg/kg) of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
arm group label: CNT0 3649 30 mcg/kg (single dose)
arm group type: Experimental
description: A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
arm group label: CNTO 3649 100 mcg/kg (single dose)
arm group type: Experimental
description: A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
arm group label: CNTO 3649 300 mcg/kg (single dose)
arm group type: Experimental
description: A single dose of 300 microgram per kilogram (mcg/kg) of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
arm group label: CNT0 3649 30 mcg/kg (multiple dose)
arm group type: Experimental
description: Participants with type 2 diabetes mellitus will be administered 30 mcg/kg CNTO 3649 as subcutaneous injection once a week for 4 weeks.
arm group label: CNTO 3649 100 mcg/kg (multiple dose)
arm group type: Experimental
description: Participants with type 2 diabetes mellitus will be administered 100 mcg/kg CNTO 3649 as subcutaneous injection once a week for 4 weeks.
arm group label: Placebo
arm group type: Placebo Comparator
description: Matching placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
intervention type: Drug
intervention name: CNTO 3649 10 mcg/kg
description: A single dose of 10 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
arm group label: CNTO 3649 10 mcg/kg (single dose)
intervention type: Drug
intervention name: CNT0 3649 30 mcg/kg
description: A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 30 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
arm group label: CNT0 3649 30 mcg/kg (multiple dose)
arm group label: CNT0 3649 30 mcg/kg (single dose)
intervention type: Drug
intervention name: CNTO 3649 100 mcg/kg
description: A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 100 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
arm group label: CNTO 3649 100 mcg/kg (multiple dose)
arm group label: CNTO 3649 100 mcg/kg (single dose)
intervention type: Drug
intervention name: CNTO 3649 300 mcg/kg
description: A single dose of 300 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
arm group label: CNTO 3649 300 mcg/kg (single dose)
intervention type: Drug
intervention name: Placebo
description: Matching Placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
arm group label: Placebo
criteria: 
gender: Male
minimum age: 20 Years
maximum age: 64 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Janssen Pharmaceutical K.K., Japan Clinical Trial
role: Study Director
affiliation: Janssen Pharmaceutical K.K.
facility: 
country: Japan
url: http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=2352&filename=CR016429_CSR.pdf
description: Safety, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Dose of CNTO 3649 in Healthy Adult Men and Multiple Subcutaneous Doses of CNTO 3649 in Patients With Type 2 Diabetes Mellitus
responsible party type: Sponsor
mesh term: Diabetes Mellitus
mesh term: Diabetes Mellitus, Type 2